Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D Global BiotechROCO:6808 -3.00%70 Quick Ratio is 13.53 as of Dec. 2025, which is 15% below its 10-year median of 15.99. GuruFocus rates ROCO:6808 with a GF Score™ of 70/100 and a GF Value™ of NT$185.91 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, 3D Global Biotech ranks better than 84.83% on this metric.
3D Global Biotech has a quick ratio of 13.53. It generally indicates good short-term financial strength.
The historical rank and industry rank for 3D Global Biotech's Quick Ratio or its related term are showing as below:
ROCO:6808'
s Quick Ratio Range Over the Past 10 Years
Min: 6.49 Med: 15.99 Max: 31.49
Current: 13.53
During the past 9 years, 3D Global Biotech's highest Quick Ratio was 31.49. The lowest was 6.49. And the median was 15.99.
ROCO:6808's Quick Ratio is ranked better than 84.83% of 1411
companies
in the Biotechnology industry
Industry Median: 3.6
vs ROCO:6808: 13.53
3D Global Biotech (ROCO:6808) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
3D Global Biotech Quick Ratio Related Terms
3D Global Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for 3D Global Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6808 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, 3D Global Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Global Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Global Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where 3D Global Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
3D Global Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3D Global Biotech (ROCO:6808) has a Quick Ratio of 13.53 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on 3D Global Biotech and its competitors. This is 15% below median its historical median of 15.99. Over the past decade, 3D Global Biotech's Quick Ratio has ranged from 6.49 to 31.49. According to the industry distribution chart, 3D Global Biotech ranks #214 out of 1411 companies in the Biotechnology industry, placing it in the top 15.2%.
Is 3D Global Biotech's Quick Ratio too high?
3D Global Biotech's current Quick Ratio of 13.53 is 15% below median its 10-year median of 15.99. Over the past 10 years, this metric has ranged from a low of 6.49 to a high of 31.49. The Biotechnology industry median Quick Ratio is 3.60. 3D Global Biotech's value of 13.53 is 275.8% above this industry median. Based on the distribution chart, 3D Global Biotech ranks #214 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3D Global Biotech has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Global Biotech's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Global Biotech ranks #214 out of 1411 companies for Quick Ratio. This places 3D Global Biotech in the top 15% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. 3D Global Biotech's value of 13.53 is 275.8% above this benchmark. Historically, 3D Global Biotech's own Quick Ratio has ranged from 6.49 to 31.49 over the past decade. While the company's 10-year median is 15.99 vs. the industry median of 3.60, 3D Global Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3D Global Biotech's current Quick Ratio of 13.53 is 275.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on 3D Global Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3D Global Biotech's current Quick Ratio is 13.53, which is 15% below median its own 10-year median of 15.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Global Biotech stock overvalued right now?
Based on GuruFocus' analysis, 3D Global Biotech (ROCO:6808) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$185.91, compared to a current price of NT$38.85 — trading 79.1% below its estimated fair value. The current Quick Ratio is 13.53, which is 15% below median its 10-year median of 15.99 and 275.8% above the Biotechnology industry median of 3.60. 3D Global Biotech's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For 3D Global Biotech (ROCO:6808), the current Quick Ratio is 13.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Global Biotech (ROCO:6808) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Global Biotech stock appears to be undervalued.
The current stock price of NT$38.85 is trading 79.1% below its estimated GF Value™ of NT$185.91.
GuruFocus considers 3D Global Biotech to be Significantly Undervalued.
Key valuation signals for ROCO:6808:
Quick Ratio: 13.53 (15% below median its 10-year median of 15.99)
GF Value™: NT$185.91 vs. price of NT$38.85 (79.1% below fair value)
Industry Position: 275.8% above the Biotechnology median (#214 of 1411)
No single metric tells the full story. See the ROCO:6808 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Global Biotech Inc is engaged in the research and development of high-end medical equipment and biological 3D printing technology and the sale of medical Materials and other related products.
70GF Score
Get the complete analysis for ROCO:6808
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6808 has been successfully added to your 
